96 related articles for article (PubMed ID: 1216856)
1. [Biochemical-pharmacological basis for the clinical use of L-dioxypheny alanine in Parkinson's syndrome].
Hornykiewicz VO
Wien Med Wochenschr; 1975 May; 125(21):325-7. PubMed ID: 1216856
[No Abstract] [Full Text] [Related]
2. [The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
Sommer H; Fischer GJ; Quandt J
Folia Clin Int (Barc); 1974 Oct; 24(10):681-95. PubMed ID: 4279185
[No Abstract] [Full Text] [Related]
3. Levodopa treatment of Parkinson's syndrome: past and future.
Pletscher A
Adv Neurol; 1990; 53():469-73. PubMed ID: 2239486
[No Abstract] [Full Text] [Related]
4. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
5. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
[No Abstract] [Full Text] [Related]
6. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Luquin MR; Scipioni O; Vaamonde J; Gershanik O; Obeso JA
Mov Disord; 1992; 7(2):117-24. PubMed ID: 1350058
[TBL] [Abstract][Full Text] [Related]
7. Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
Zigmond MJ; Hastings TG; Abercrombie ED
Ann N Y Acad Sci; 1992 May; 648():71-86. PubMed ID: 1637074
[No Abstract] [Full Text] [Related]
8. Apomorphine increases blood glucose concentrations in Parkinson's disease.
Tison F; Fouillet N; Henry P
Clin Neuropharmacol; 1994 Feb; 17(1):92-5. PubMed ID: 8149364
[TBL] [Abstract][Full Text] [Related]
9. Long-term course in Parkinson's syndrome and cerebral polypathy (Parkinson plus).
Fischer PA
Adv Neurol; 1987; 45():235-8. PubMed ID: 3825695
[No Abstract] [Full Text] [Related]
10. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
Mercuri NB; Scarponi M; Federici M; Bonci A; Siniscalchi A; Bernardi G
Ann Neurol; 1998 May; 43(5):613-7. PubMed ID: 9585355
[TBL] [Abstract][Full Text] [Related]
11. Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
Melamed E; Globus M; Rosenthal J; Uzzan A
Adv Neurol; 1987; 45():507-10. PubMed ID: 3825730
[No Abstract] [Full Text] [Related]
12. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
[No Abstract] [Full Text] [Related]
13. Cerebral blood flow in Parkinson's syndrome.
Granérus AK; Nilsson NJ; Suurküla M; Svanborg A
Adv Neurol; 1984; 40():403-5. PubMed ID: 6695620
[No Abstract] [Full Text] [Related]
14. Observations made with L-deprenil (Jumex) in the long-term treatment of outpatients with Parkinson's syndrome.
Gyimóti G; Csanaky A; Leposa D
Ther Hung; 1983; 31(1):26-30. PubMed ID: 6443750
[No Abstract] [Full Text] [Related]
15. [The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
Wang W; Zhao DZ; Sun XF; Gu SD
Zhongguo Zhong Yao Za Zhi; 2002 May; 27(5):368-70. PubMed ID: 12774329
[TBL] [Abstract][Full Text] [Related]
16. Development of new pharmacological approaches in Parkinson's disease.
Carlsson A
Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631
[No Abstract] [Full Text] [Related]
17. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Xu DL; Yu WC; Pan GB; Chen SD
Adv Neurol; 1987; 45():587-90. PubMed ID: 2881450
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of Parkinson's syndrome using a new preparation from the series of tricyclic psychotropic drugs].
Deze J; Völler GW
Med Welt; 1975 Aug; 26(33-34):1457-62. PubMed ID: 1100988
[No Abstract] [Full Text] [Related]
19. A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
Lapchak PA
Mov Disord; 1998; 13 Suppl 1():49-54. PubMed ID: 9613719
[TBL] [Abstract][Full Text] [Related]
20. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
Castaigne P; Rondot P; Taberlet A; Baumann N
Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
[No Abstract] [Full Text] [Related]
[Next] [New Search]
